Rishi P, et al. - This trial incorporated an investigation of the vitreoretinal (VR) complications and therapeutic outcomes in eyes undergoing modified osteo-odonto-keratoprosthesis (mOOKP) surgery. Findings revealed that vitreoretinal complication served as a major cause of visual morbidity in eyes undergoing mOOKP surgery. These complications presented a challenging situation to manage. Nevertheless, encouraging results could be obtained via appropriate and timely intervention.

Methods

• The scheme of this research was a retrospective case series study.
• The recruitment consisted of all patients who underwent modified OOKP (mOOKP) surgery at a tertiary eye-care center from March 2003 to February 2013.
• An appraisal was conducted of the medical records for relevant medical history, best-corrected visual acuity (BCVA), slit-lamp examination, ultrasound scan, oral examination findings, and VR complications.
• BCVA at the last visit was included as the primary outcome.
• Herein, optimal anatomic outcome constituted attached retina with a normal intraocular pressure at the last visit.

Results

• Researchers examined 92 eyes of 90 patients.
• Stevens-Johnson syndrome (n = 53), chemical injury (n = 36) and ocular cicatricial pemphigoid (n = 3) were determined to be the indicators for OOKP.
• VR complications were reported in 41 eyes of 39 patients, with the inclusion of vitritis (n = 21), retinal detachment (RD) (n = 12; primary RD = 5), retroprosthetic membrane (RPM) (n = 10; primary RPM = 2), endophthalmitis (n = 8), vitreous hemorrhage (VH) (n = 5; primary VH = 1), serous choroidal detachment (n = 5), hemorrhagic choroidal detachment (n = 2), and leak-related hypotony (n = 1).
• As per outcomes, the mean interval from mOOKP surgery to occurrence of VR complication(s) was 43.8 months (median, 41.9 months; range, 0.2-95.5 months).
• Visual improvement was illustrated in 17 eyes (42%) (mean improvement = 1.2 logarithm of the minimum angle of resolution [logMAR]; median, 0.8 logMAR; range, 0.1-2.5 logMAR), visual decline in 7 eyes (14%) (mean decline in BCVA = 0.6 logMAR; median, 0.4 logMAR; range, 0.3-1.8 logMAR) following the treatment of VR complication.
• No difference was found in BCVA, in 17 eyes (42%).
• Nevertheless, BCVA ≥6/60 was retained in 19 eyes and ≥6/18 was retained in 9 eyes following final VR treatment.